Compare YMT & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YMT | LPCN |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | China | United States |
| Employees | 673 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 19.1M |
| IPO Year | N/A | 2011 |
| Metric | YMT | LPCN |
|---|---|---|
| Price | $0.51 | $2.46 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 211.0K | 87.8K |
| Earning Date | 06-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,976,677.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $92.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.12 | $1.81 |
| 52 Week High | $2.85 | $12.37 |
| Indicator | YMT | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 42.58 | 53.89 |
| Support Level | $0.40 | $2.16 |
| Resistance Level | $0.62 | $2.67 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 43.41 | 55.96 |
Yimutian Inc operates an agricultural B2B platform in China. It provides a comprehensive set of digital solutions to facilitate agricultural product transactions, ranging from searching and matching to transaction facilitation and settlement, through its Yimutian App and Douniu App. Additionally, leveraging its industry experience and market insights, the company has ventured into the realm of smart farming and agricultural sourcing and trading, further broadening its commercialization channels and animating its other business lines. The company operates as a single operating and reportable segment, as it offers a unified set of products and services mainly related to the provision of digital agricultural transaction services.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.